{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:07:43Z","timestamp":1788444463602,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.clml.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T18:07:28Z","timestamp":1711562848000},"page":"433-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions"],"prefix":"10.1016","volume":"24","author":[{"given":"Lara","family":"Gallucci Figorelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peterson Tiago","family":"Galv\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Matheus Ribeiro","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Marimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia","family":"Pentagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane","family":"Milito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony","family":"Schaffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-5486","authenticated-orcid":false,"given":"Katia","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2024.03.010_bib0001","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.03.010_bib0002","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2009.19","article-title":"Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy","volume":"23","author":"Wang","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.03.010_bib0003","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MOH.0000000000000434","article-title":"SOX11, a key oncogenic factor in mantle cell lymphoma","volume":"25","author":"Beekman","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"10.1016\/j.clml.2024.03.010_bib0004","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"issue":"8580","key":"10.1016\/j.clml.2024.03.010_bib0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(88)90367-4","article-title":"Updated Kiel classification for lymphomas","volume":"331","author":"Stansfeld","year":"1988","journal-title":"The Lancet"},{"key":"10.1016\/j.clml.2024.03.010_bib0006","series-title":"In: Histopathology of Non-Hodgkin\u2019s Lymphomas","first-page":"13","article-title":"The Kiel Classification","author":"Lennert","year":"1992"},{"issue":"10","key":"10.1016\/j.clml.2024.03.010_bib0007","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"Summary and description of a working formulation for clinical usage","volume":"49","year":"1982","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clml.2024.03.010_bib0008","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma a proposal for unification of morphologic, immunologic, and molecular data","volume":"16","author":"Banks","year":"1992","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.clml.2024.03.010_bib0009","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2011.047357","article-title":"Indolent mantle cell lymphoma","volume":"96","author":"Furtado","year":"2011","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2024.03.010_bib0010","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.03.010_bib0011","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.clml.2024.03.010_bib0012","doi-asserted-by":"crossref","first-page":"871","DOI":"10.5858\/arpa.2012-0197-CR","article-title":"Transformation of indolent mantle cell lymphoma to pleomorphic mantle cell lymphoma: case report and review of clinical and morphologic variants","volume":"136","author":"Kiel","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.clml.2024.03.010_bib0013","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.03.010_bib0014","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","article-title":"Incidence and survival trends in mantle cell lymphoma","volume":"181","author":"Epperla","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2024.03.010_bib0015","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.clml.2024.03.010_bib0016","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-Cell Lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2024.03.010_bib0017","first-page":"1947","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Kami","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.03.010_bib0019","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3324\/haematol.2009.013359","article-title":"Mantle cell lymphoma","volume":"94","author":"Pileri","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.03.010_bib0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11864-003-0003-1","article-title":"Mantle cell lymphoma","volume":"4","author":"Densmore","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clml.2024.03.010_bib0021","series-title":"The EBMT Handbook","first-page":"643","article-title":"Mantle Cell Lymphoma","author":"Dietrich","year":"2019"},{"issue":"15","key":"10.1016\/j.clml.2024.03.010_bib0022","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.7314\/APJCP.2015.16.15.6591","article-title":"Ki-67 Labeling Indices in \u201cClassic\u201d versus \u201cBlastoid\u201d Mantle Cell Lymphomas - Proposed Cutoff Values for Routine Diagnostic Workup","volume":"16","author":"Pervez","year":"2015","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"issue":"5","key":"10.1016\/j.clml.2024.03.010_bib0023","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.hoc.2020.06.009","article-title":"Blastoid mantle cell lymphoma","volume":"34","author":"Jain","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"26","key":"10.1016\/j.clml.2024.03.010_bib0024","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","article-title":"Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!","volume":"132","author":"Dreyling","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.03.010_bib0025","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype","volume":"15","author":"Bernard","year":"2001","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.03.010_bib0026","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0959-8049(02)00456-2","article-title":"Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma","volume":"39","author":"R\u00e4ty","year":"2003","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clml.2024.03.010_bib0027","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.1997.15.4.1664","article-title":"Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants","volume":"15","author":"Majlis","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2024.03.010_bib0028","doi-asserted-by":"crossref","first-page":"151533","DOI":"10.1016\/j.anndiagpath.2020.151533","article-title":"Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing","volume":"46","author":"Polonis","year":"2020","journal-title":"Ann Diagn Pathol"},{"issue":"7","key":"10.1016\/j.clml.2024.03.010_bib0029","first-page":"2253","article-title":"Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma","volume":"95","author":"Yatabe","year":"2000","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.03.010_bib0030","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"Journal of Clinical Investigation"},{"issue":"10","key":"10.1016\/j.clml.2024.03.010_bib0031","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.5858\/2000-124-1457-MIAOTC","article-title":"Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma","volume":"124","author":"Izban","year":"2000","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0032","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mdp495","article-title":"Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma","volume":"21","author":"Schaffel","year":"2010","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1016\/j.clml.2024.03.010_bib0033","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0034","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijc.2910310104","article-title":"Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation","volume":"31","author":"Gerdes","year":"1983","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijc.2910310104","article-title":"Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation","volume":"31","author":"Gerdes","year":"1983","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.clml.2024.03.010_bib0036","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.03.010_bib0037","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/bloodadvances.2022009225","article-title":"Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma","volume":"7","author":"Epperla","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0038","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.03.010_bib0039","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.hoc.2020.06.002","article-title":"Watch and Wait in Mantle Cell Lymphoma","volume":"34","author":"Lee","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"10.1016\/j.clml.2024.03.010_bib0040","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","article-title":"Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression\u2013based proliferation signature","volume":"25","author":"Salaverria","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2024.03.010_bib0041","series-title":"Molecular Investigations of High-Risk Mantle Cell Lymphoma: Genetic Factors and the Impact of the Microenvironment","author":"Joana de Matos","year":"2022"},{"issue":"3","key":"10.1016\/j.clml.2024.03.010_bib0042","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0959-8049(01)00366-5","article-title":"A Danish population-based analysis of 105 mantle cell lymphoma patients","volume":"38","author":"Andersen","year":"2002","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.clml.2024.03.010_bib0046","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.clml.2024.03.010_bib0047","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3390\/cancers14112673","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma; insights into its potential role in the era of new immunotherapeutic and targeted therapies: the GETH\/GELTAMO experience","volume":"14","author":"Gutierrez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.03.010_bib0048","doi-asserted-by":"crossref","first-page":"102651","DOI":"10.1016\/j.ctrv.2023.102651","article-title":"Recent advances in genomics and therapeutics in mantle cell lymphoma","volume":"122","author":"Lu","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"10.1016\/j.clml.2024.03.010_bib0049","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle\u2013cell lymphoma with zanubrutinib, a selective inhibitor of bruton\u2019s tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clml.2024.03.010_bib0050","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.03.010_bib0051","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1073\/pnas.91.2.709","article-title":"Function of a human cyclin gene as an oncogene","volume":"91","author":"Hinds","year":"1994","journal-title":"Proc Natl Acad Sci"},{"issue":"17","key":"10.1016\/j.clml.2024.03.010_bib0052","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.03.010_bib0053","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1016\/j.clml.2024.03.010_bib0054","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","article-title":"Advances in the understanding of mantle cell lymphoma","volume":"142","author":"Jares","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.03.010_bib0055","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/0008-5472.CAN-21-2709","article-title":"Targeting the P53 protein for cancer therapies: the translational impact of P53 research","volume":"82","author":"Levine","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0056","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5015","key":"10.1016\/j.clml.2024.03.010_bib0057","first-page":"49","article-title":"p53 Mutations in Human Cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science (1979)"},{"issue":"2","key":"10.1016\/j.clml.2024.03.010_bib0058","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain-of-function in cancer","volume":"2","author":"Oren","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"14","key":"10.1016\/j.clml.2024.03.010_bib0059","doi-asserted-by":"crossref","first-page":"8424","DOI":"10.1073\/pnas.1431692100","article-title":"Understanding the function\u2013structure and function\u2013mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis","volume":"100","author":"Kato","year":"2003","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1016\/j.clml.2024.03.010_bib0060","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.03.010_bib0061","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.03.010_bib0062","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma\u2014consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"issue":"10","key":"10.1016\/j.clml.2024.03.010_bib0063","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.03.010_bib0064","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.clml.2018.11.007","article-title":"Aggressive leukemic non-nodal mantle cell lymphoma with P53 gene rearrangement\/mutation is highly responsive to rituximab\/ibrutinib combination therapy","volume":"19","author":"Mori","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.clml.2024.03.010_bib0065","article-title":"Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma","volume":"36","year":"2010","journal-title":"Int J Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.03.010_bib0066","article-title":"Impact of p53 disruption on mantle cell lymphoma (MCL) treatment out-come, multi-centre retrospective study","volume":"138","author":"Elhassadi","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0067","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0068","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.03.010_bib0069","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3816\/CLM.2009.n.055","article-title":"Mantle cell lymphoma: biological insights and treatment advances","volume":"9","author":"Leonard","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"9","key":"10.1016\/j.clml.2024.03.010_bib0070","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0071","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s13046-019-1458-7","article-title":"Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on delta-like ligand 4 and is a potential target for specific antibody therapy","volume":"38","author":"Silkenstedt","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clml.2024.03.010_bib0072","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4161\/cc.4.5.1673","article-title":"How disruption of cell cycle regulators might predispose to sun-induced skin cancer","volume":"4","author":"R\u00fcnger","year":"2005","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.clml.2024.03.010_bib0073","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/303001","article-title":"A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families","volume":"67","author":"Ciotti","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"16","key":"10.1016\/j.clml.2024.03.010_bib0074","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-3709","article-title":"TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0075","doi-asserted-by":"crossref","first-page":"14383","DOI":"10.1038\/s41598-018-32569-x","article-title":"CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making","volume":"8","author":"Worst","year":"2018","journal-title":"Sci Rep"},{"issue":"30","key":"10.1016\/j.clml.2024.03.010_bib0076","doi-asserted-by":"crossref","first-page":"50071","DOI":"10.18632\/oncotarget.18412","article-title":"CDKN2A methylation in esophageal cancer: a meta-analysis","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"issue":"45","key":"10.1016\/j.clml.2024.03.010_bib0077","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.clml.2024.03.010_bib0078","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.03.010_bib0079","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.embor.7400210","article-title":"ATM and ataxia telangiectasia","volume":"5","author":"McKinnon","year":"2004","journal-title":"EMBO Rep"},{"issue":"12","key":"10.1016\/j.clml.2024.03.010_bib0080","doi-asserted-by":"crossref","first-page":"10280","DOI":"10.3390\/ijms241210280","article-title":"NOTCH signaling in mantle cell lymphoma: biological and clinical implications","volume":"24","author":"Deshotels","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5\u20136","key":"10.1016\/j.clml.2024.03.010_bib0081","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther"},{"issue":"19","key":"10.1016\/j.clml.2024.03.010_bib0082","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"10197","key":"10.1016\/j.clml.2024.03.010_bib0083","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","article-title":"Pharmacogenomics","volume":"394","author":"Roden","year":"2019","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0084","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdx707","article-title":"The European Society for Medical Oncology (ESMO) precision medicine glossary","volume":"29","author":"Yates","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41698-017-0016-z","article-title":"Precision medicine: the foundation of future cancer therapeutics","volume":"1","author":"Shin","year":"2017","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.clml.2024.03.010_bib0086","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2020.07.009","article-title":"Precision medicine in non-small cell lung cancer: current applications and future directions","volume":"84","author":"Yang","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.clml.2024.03.010_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"42","key":"10.1016\/j.clml.2024.03.010_bib0088","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/EDBK_349509","article-title":"New Directions for Mantle Cell Lymphoma in 2022","author":"Kumar","year":"2022","journal-title":"Am Soc Clin Oncol Educ"},{"issue":"13","key":"10.1016\/j.clml.2024.03.010_bib0089","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"issue":"30","key":"10.1016\/j.clml.2024.03.010_bib0090","doi-asserted-by":"crossref","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"issue":"S1","key":"10.1016\/j.clml.2024.03.010_bib0091","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.3149","article-title":"Mantle cell lymphoma\u2014update on molecular biology, prognostication and treatment approaches","volume":"41","author":"Silkenstedt","year":"2023","journal-title":"Hematol Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T21:21:39Z","timestamp":1718745699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":87,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2152265024001356"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}